Pulmonx
€1.14
2
+€0.06+5.56% Today
Statistics
Day High
1.05
Day Low
1.05
52W High
6.1
52W Low
0.99
Volume
-
Avg. Volume
-
Mkt Cap
47.02M
P/E Ratio
-
Dividend Yield
-
Dividend
-
Upcoming
Dividends
0%Dividend Yield
Mar 18
€12.17
Sep 17
€12.79
Mar 17
€4.65
Mar 16
€22.14
Sep 15
€13.32
10Y Growth
N/A
5Y Growth
N/A
3Y Growth
N/A
1Y Growth
N/A
Earnings
5MayExpected
Expected EPS
-0.326667
Actual EPS
N/A
Financials
-67.23%Profit Margin
Unprofitable159.08MRevenue
-106.95MNet Income
Analyst Ratings
$5.82Average Price Target
The highest estimate is 10.62.
From 3 ratings within the last 6 months. This is not an investment recommendation.
From 3 ratings within the last 6 months. This is not an investment recommendation.
Buy 100%
Hold 0%
Sell 0%
People Also Follow
This list is based on the watchlists of people on Stock Events who follow 4NI.F. It's not an investment recommendation.
Competitors
This list is an analysis based on recent market events. It's not an investment recommendation.
B2gold
BTG
Mkt Cap6.35B
Medtronic
MDT
Mkt Cap111.22B
Boston Scientific
BSX
Mkt Cap93.36B
Johnson & Johnson
JNJ
Mkt Cap585.7B
Koninklijke Philips N.V.
PHG
Mkt Cap25.99B
Smith & Nephew
SNN
Mkt Cap13.72B
Intuitive Surgical
ISRG
Mkt Cap160.56B
Hologic
HOLX
Mkt Cap16.89B
About
Pulmonx Corporation, a medical technology company, provides minimally invasive devices for the treatment of chronic obstructive pulmonary diseases. It offers Zephyr Endobronchial Valve, a solution for the treatment of bronchoscopic in adult patients with hyperinflation associated with severe emphysema; and Chartis Pulmonary Assessment System, a balloon catheter and console system with flow and pressure sensors that are used to assess the presence of collateral ventilation. The company also provides StratX Lung Analysis Platform, a cloud-based quantitative computed tomography analysis service that offers information on emphysema destruction, fissure completeness, and lobar volume to help identify target lobes for the treatment with Zephyr Valves. It serves emphysema patients in the United States, Europe, the Middle East, Africa, the Asia-Pacific, and internationally. The company was formerly known as Pulmonx and changed its name to Pulmonx Corporation in December 2013. Pulmonx Corporation was incorporated in 1995 and is headquartered in Redwood City, California.
Show more...
CEO
Employees
7859
Country
DE
ISIN
US7458481014
WKN
000A2P1AF
Listings
0 Comments
Share your thoughts
FAQ
What is Pulmonx stock price today?▼
The current price of 4NI.F is €1.14 EUR — it has increased by +5.56% in the past 24 hours. Watch Pulmonx stock price performance more closely on the chart.
What is Pulmonx stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Pulmonx stocks are traded under the ticker 4NI.F.
Is Pulmonx stock price growing?▼
4NI.F stock has fallen by -0.87% compared to the previous week, the month change is a -14.29% fall, over the last year Pulmonx has showed a -80.84% decrease.
What is Pulmonx market cap?▼
Today Pulmonx has the market capitalization of 47.02M
When is the next Pulmonx earnings date?▼
Pulmonx is going to release the next earnings report on May 05, 2026.
What were Pulmonx earnings last quarter?▼
4NI.F earnings for the last quarter are -0.21 EUR per share, whereas the estimation was -0.33 EUR resulting in a +35.06% surprise. The estimated earnings for the next quarter are N/A EUR per share.
What is Pulmonx revenue for the last year?▼
Pulmonx revenue for the last year amounts to 159.08M EUR.
What is Pulmonx net income for the last year?▼
4NI.F net income for the last year is -106.95M EUR.
Does Pulmonx pay dividends?▼
Yes, 4NI.F dividends are paid annual. The last dividend per share was 12.17 EUR. As of today, Dividend Yield (FWD)% is 0%.
How many employees does Pulmonx have?▼
As of April 07, 2026, the company has 7,859 employees.
In which sector is Pulmonx located?▼
Pulmonx operates in the Health Care sector.
When did Pulmonx complete a stock split?▼
Pulmonx has not had any recent stock splits.